Loading…
Scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru, an autonomous institute of the Department of Science and Technology, have developed a small fluorescent molecule named TZ-48 that reports the presence of amyloid-beta, the principal biomarker of Alzheimer's disease.
TZ-48 signals amyloid-beta fibrils in two ways at once - it switches on its fluorescence on binding, and it shows a distinct fluorescence lifetime, which together allow selective and differential detection.
The team built the probe into ADxFluor, a smartphone-integrated platform that captures and quantifies the fluorescence change, turning a laboratory measurement into a reading a phone can take.
TZ-48 crosses the blood-brain barrier, labels amyloid plaques in the brains of transgenic Alzheimer's mice, and works with confocal laser scanning microscopy and fluorescence lifetime imaging; it also detects amyloid-beta in cerebrospinal fluid and blood serum, separating diseased from healthy mice.
The work was published in the journal ACS Chemical Neuroscience and announced on 25 August 2026; the team includes Krithi K. Bhagavath, Madhu Ramesh, Yogendra Kumar, Sabyasachi Mandal, Hiriyakkanavar Ila and Thimmaiah Govindaraju.
A turn-on probe is close to dark on its own and lights up only when it binds its target, so the signal itself is the evidence of binding - there is no need to wash away unbound dye and hope the background is clean. Fluorescence lifetime is a second, independent read-out: it measures how long the molecule stays in its excited state before emitting, typically nanoseconds, and that interval changes with the local environment the probe finds itself in. Because lifetime does not depend on how much probe is present or how bright the lamp is, it is far more robust than raw intensity. TZ-48 uses both channels together, which is what lets it tell amyloid-beta fibrils apart from other species rather than merely reporting that something is there.
Simple Analogy: Intensity tells you how loudly a bell is ringing; lifetime tells you how long it goes on ringing. The pitch and the decay together identify which bell it is, even if you cannot control how hard it was struck.
Autonomous research institute of the Department of Science and Technology, set up in 1989 to mark the birth centenary of Jawaharlal Nehru; it works across materials science, molecular biology, neuroscience and theoretical sciences, and has been a deemed-to-be university since 2002
Nodal central department for promoting new areas of science and technology; JNCASR is one of its autonomous institutions
Observed on 21 September each year, with the whole of September marked as World Alzheimer's Month; the campaign is run by Alzheimer's Disease International, founded in 1984, which publishes the annual World Alzheimer Report.
Alzheimer's has two pathological hallmarks - amyloid plaques and tau tangles. TZ-48 reports the amyloid side only, so it is not a complete pathological picture.
The selective barrier between blood and brain tissue is the reason most drugs and probes fail to reach the brain; TZ-48's reported permeability is what allows it to label plaques in brain tissue rather than only in extracted samples.
The nationwide survey of older adults that underpins India's dementia prevalence estimates; a standard citation for any question on the health burden of population ageing.
GS Paper 3 > Science and Technology: Developments and Applications in Everyday Life; Indigenous Technology
General Awareness > Science and Technology in the News
General Awareness > Current Affairs
A peptide that misfolds and aggregates into fibrils, depositing as the extracellular plaques characteristic of Alzheimer's disease.
A probe design in which the molecule is nearly non-fluorescent until it binds its target, so the emission itself is the detection signal.
The average time a molecule remains in its excited state before emitting light; independent of probe concentration, which makes it a robust read-out.
The selective barrier formed by brain capillary endothelial cells that blocks most molecules in the bloodstream from entering brain tissue.
A mouse carrying introduced human disease genes so that it develops the pathology under study - here, amyloid plaques.